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Abstract
Background and Objectives Untreated phenylketonuria
(PKU), a hereditary metabolic disorder caused by a genetic
mutation in phenylalanine hydroxylase (PAH), is charac-
terized by elevated blood phenylalanine (Phe) and severe
neurologic disease. Sapropterin dihydrochloride, a syn-
thetic preparation of naturally occurring PAH cofactor
tetrahydrobiopterin (BH4), activates residual PAH in a
subset of patients, resulting in decreased blood Phe and
increased Phe tolerance. The objective of this study was to
determine the appropriate dose of sapropterin in pediatric
patients (0–6 years). The study design used D-optimization
and was prospectively powered to achieve precise esti-
mates of clearance and volume of distribution.
Methods Oral sapropterin (5 or 20 mg/kg) was adminis-
tered once daily. Sapropterin plasma concentrations were
measured by a validated method. Population pharmacoki-
netic analysis was performed with NONMEM version 7.2
on pooled data from 156 pediatric and adult PKU patients
in two phase III clinical studies.
Results The best pharmacokinetic model was a one-
compartment model with an absorption lag, first-order
input, and linear elimination, with a factor describing
endogenous BH4 levels. Body weight was the only
covariate significantly affecting sapropterin
pharmacokinetics. Based on recommended dosing, expo-
sure across age groups was comparable. The absorption
rate and terminal half-life suggest flip-flop pharmacoki-
netic behavior where absorption is rate limiting.
Conclusion The effect of weight on sapropterin pharma-
cokinetics was significant and exposure was comparable
across age groups; thus, weight-based dosing is appropri-
ate. The doses selected for pediatric patients provided
similar exposure as in adults. Given the slow absorption
and elimination half-life, once-daily dosing is justified.
Key Points
Population pharmacokinetics of sapropterin
dihydrochloride, a synthetic preparation of naturally
occurring phenylalanine hydroxylase cofactor
tetrahydrobiopterin (BH4), were evaluated in
pediatric phenylketonuria patients.
The best pharmacokinetic model was a one-
compartment model with an absorption lag, first-
order input, and linear elimination, with a factor
describing endogenous BH4 levels. Body weight was
the only covariate significantly affecting sapropterin
pharmacokinetics.
The doses selected for pediatric patients provided
similar exposure as in adults.
1 Introduction
Phenylketonuria (PKU) is a hereditary metabolic disorder
caused by a genetic mutation and deficiency in
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phenylalanine hydroxylase (PAH), an enzyme required for
the metabolism of phenylalanine (Phe). In PKU patients,
PAH is mutated to varying degrees and if active PAH is not
present in sufficient quantities, Phe accumulates to abnor-
mally high levels in the blood and brain; this often results
in mental retardation and brain damage, mental illness,
seizures, tremors, and cognitive problems. Tetrahydrobi-
opterin (BH4), a cofactor for PAH, facilitates the hydrox-
ylation of Phe to tyrosine, thereby maintaining appropriate
levels of plasma Phe. Several studies have shown a
reduction in plasma Phe levels in some PKU patients
treated with a synthetic preparation of the dihydrochloride
salt of naturally occurring BH4 (sapropterin dihydrochlo-
ride; sapropterin) [1–3].
A population pharmacokinetic model of data arising
from study PKU-004, which assessed sapropterin levels
in children (C9 years of age) and adults, found a two-
compartment model with endogenous BH4 provided the
best description of the data [4]. The population phar-
macokinetic model from this study was used to design
an optimal pharmacokinetic sampling strategy for study
PKU-015, a population pharmacokinetic study to char-
acterize pharmacokinetic characteristics of BH4 in
pediatric patients from 0 to 6 years of age, and provide
dosing recommendations for this population. The study
design used D-optimization [5–7] based on the previous
pharmacokinetic model and was prospectively powered
to achieve precise estimates of apparent total clearance
of the drug from plasma after oral administration (CL/F)
and apparent volume of distribution of the central
compartment (Vc/F) in each age group.
Graphical examination of the concentration–time data
arising from PKU-015 suggested that there were little data
supporting a peripheral compartment, which was reflected
in the poor precision of the estimates for the associated
parameters in the previous evaluation (Electronic Supple-
mentary Material Fig. 1S). Thus, pooled data from studies
PKU-004 and PKU-015 were fit to ensure a pharmacoki-




Both studies (PKU-015 and PKU-004) were approved by
institutional review boards or ethics committees at all
centers and were performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki
and its later amendments. Informed written consent was
obtained from all patients or their guardian, in the case of
children, before inclusion in the study.
2.1.1 Study PKU-015
Study PKU-015 was an open-label, multicenter study
conducted at 19 centers in the USA and Canada. The study
was designed to evaluate the safety and population phar-
macokinetics of sapropterin, and the effect of sapropterin
on neurocognitive development and blood Phe levels in
infants and young children with PKU. A total of 95 patients
(0–6 years old) received oral sapropterin at a dose of
20 mg/kg once daily (at the same time each day) with food
for 4 weeks. Subjects were eligible to participate in the
population pharmacokinetic substudy and were enrolled by
age at study entry. A total of 94 subjects were enrolled in
the pharmacokinetic substudy and 80 of these subjects
were evaluable. D-optimization was used to select the
pharmacokinetic sample times and identify the number of
patients needed to estimate the pharmacokinetic parame-
ters. The study was prospectively powered to achieve
precise estimates of CL/F and Vc/F in each age group.
2.1.2 Study PKU-004
Study PKU-004 was a multicenter, intra-patient, dose-
escalation, open-label extension study conducted at 26
centers in North America (Canada and the USA) and
Europe (France, Germany, Ireland, Italy, Poland, and the
UK). The study was designed to evaluate the long-term
safety and efficacy of various doses of sapropterin in
patients C8 years old with PKU who had previously
responded to sapropterin treatment. Study PKU-004
occurred in two parts. In part 1, patients received saprop-
terin in three consecutive 2-week courses of daily single
oral doses of 5 mg/kg, followed by 20 mg/kg/day, and
finally 10 mg/kg/day for 4 more weeks. Following com-
pletion of the 4-week 10 mg/kg/day period in part 1 of
PKU-004, each patient was enrolled in part 2, a 16-week
fixed-dose period during which the daily dose of saprop-
terin was fixed within the range of 5–20 mg/kg/day on the
basis of the patient’s Phe level at the end of the 2-week
10 mg/kg treatment period. A total of 80 subjects were
enrolled in study PKU-004. After completing the first
16 weeks of treatment, 78 subjects were enrolled and
evaluable in the pharmacokinetic substudy.
2.2 Pharmacokinetic Sampling
In PKU-015, three plasma samples from each patient in the
B1 year old age group and four plasma samples from each
patient in the [1 year old age group were collected at the
week 0 through week 4 visits according to a D-optimized
design shown in Table 1.
In PKU-004, four plasma samples from each patient
were collected from each patient at any point during the
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week 16, 20, or 22 visits according to a D-optimized design
shown in Table 1. Patients receiving 10 mg/kg/day in the
fixed-dose period could be assigned to Group 1 or Group 2,
but were to follow the prescribed sample assessment
schedule for that group once they had been assigned.
2.3 Tetrahydrobiopterin Assay
As BH4 is unstable in plasma, its concentration was mea-
sured indirectly by oxidizing BH4 to L-biopterin; mea-
suring the concentration of L-biopterin, which has been
shown to be stable [4, 8]; and correcting for the oxidative
conversion of BH4 to L-biopterin. The collected plasma
samples were shipped frozen on dry ice to a central labo-
ratory for assay. Samples were oxidized and assayed for
L-biopterin by a validated analytical liquid chromatogra-
phy/tandem mass spectrometry method.
The plasma concentration of BH4 was calculated from
the measured concentration of L-biopterin by correcting for
the oxidation conversion ratio of BH4 to L-biopterin,
which was determined in the assay validation as the molar
ratio, according to equation (Eq. 1):
% BH4 conversion ratio =





where MWBH4 is 241.2 g/mol and MWBiopterin is
237.2 g/mol. The nominal conversion ratio of BH4 to
L-biopterin was determined to be 47.3 %. The conver-
sion ratio was stable within at least 8 weeks of sample
storage at -70 C.
The lower limit of quantitation was 5.00 ng/mL for
L-biopterin and 10.7 ng/mL for BH4.
2.4 Pharmacokinetic Modeling
The pharmacokinetic data used in the population
analysis included all available concentration data
collected from studies PKU-015 and PKU-004. Data
from study PKU-015 were intended to be evaluated
separately from study PKU-004, or if needed using an
informative prior based on the previously developed
population pharmacokinetic model [4]. However, ini-
tial graphical evaluation of data from study PKU-015,
together with preliminary model-based evaluations,
suggested that the data for both studies were ade-
quately described using a one-compartment model
with a parameter for endogenous BH4, rather than a
two-compartment model as reported for PKU-004 [4].
Subsequently, the data from studies PKU-015 and
PKU-004 were pooled for population pharmacokinetic
model development.
Table 1 D-optimal sampling design in study PKU-015 and study PKU-004
Age group (years) Dose (mg/kg/day) Visit (week) Optimal sampling time (h) Post-dose sampling window
Lower bound (h) Upper bound (h)
Study PKU-015
0 to \1 20 1 Pre-dose – –
2 Pre-dose – –
1, 2, 3, or 4 4.9 4.5 5.5
[1 to 6 20 0 Pre-dose
2, 3, and/or 4a 0.22 0.12 1.2
2, 3, and/or 4a 3.2 2.6 5.2
2, 3, and/or 4a 7 6 8
Study PKU-004









a Subjects could have all three samples drawn at one visit, at two of the three visits, or have one sample drawn at each of the three visits
b It was recommended that one sample be taken before dosing and one within the first 10 min after dosing
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2.4.1 Structural Model and Covariate Model
A series of different structural models were evaluated in
the present analysis, including one- and two-compartment
models with first-order input, with and without an
absorption lag. The best pharmacokinetic model was a one-
compartment model with an absorption lag, first-order
input, and linear elimination, with a factor describing
endogenous BH4 levels. Covariates evaluated in the model
development are listed in Electronic Supplementary
Material Table 1S and body weight was the only covariate
significantly affecting sapropterin pharmacokinetics. The
first-order conditional estimation (FOCE) method was used
because the change in objective function value (DOFV) has
been found to more reliably follow a chi-square
distribution.
Continuous covariates such as age or weight were
modeled using a general power function, according to
Eq. 2:




where the typical value of the parameter (TVP) represents
the predicted pharmacokinetic parameter (CL/F, Vc/F) for
the ‘reference’ individual with covariate value(s) covi, Ppop
represents the population central tendency for the phar-
macokinetic parameter TVP, covi represents the individual
value for that covariate normalized by the approximate
median value for the patient population, and hi represents a
scale factor relating the covariate function to the pharma-
cokinetic parameter. A typical adult (e.g., 70 kg body
weight) was chosen as the reference individual to allow
comparison of the results in pediatrics with those in adults.
Categorical covariates (e.g., race) were modeled using
the general Eq. 3:
TVP ¼ Ppop  hcovii ð3Þ
where covi is either 0 for the standard or reference patient,
or 1 for the comparative patient. Ppop represents the value
for the pharmacokinetic parameter when covi is 0 and hi
represents a scale factor for the influence of that covariate
on the pharmacokinetic parameter.
Covariates were first examined for potential effect on
structural parameters by graphical assessment in Xpose
4.3.5 running on R3.0.2, followed by a model-based ana-
lysis if any trend was observed. A standard approach was
used in covariate evaluation. During individual covariate
evaluations, a P value of 0.005 was used to select covari-
ates; a full model was built with all identified covariates
and a P value of 0.001 was used to reduce the model
during backwards elimination. Covariate factors were
considered clinically relevant and accepted in the model if
the magnitude of the change of the parameter due to a
covariate influence resulted in C20 % variation of the
parameter. The precision of the estimated covariate effect
was also considered; covariate factors were not accepted
unless the parameter precision was \30 %.
2.4.2 Statistical Model
Inter-individual variability was described using the fol-
lowing exponential error model, according to Eq. 4:
Pj ¼ TVP  egj ð4Þ
where Pj is the individual value for the pharmacokinetic
parameter in the jth individual and gj is an independent
random variable with a mean of zero and variance xP
2.
Between-occasion variability was also assessed.
The residual variability for the pharmacokinetic model
was described using a constant coefficient of variation
(CCV) model based on the log transform both sides
(LTBS) approach according to Eq. 5:
Ln Cpij
  ¼ Ln C^pij
 þ eij1 ð5Þ
where Cˆpij is the ith plasma concentration for the jth
individual predicted by the model, Cpij is the measured
concentration, and eij is the residual error normally dis-
tributed with mean zero and variance r2.
2.4.3 Model Selection Criteria
Model building followed standard criteria [9, 10].
Decision making during model building was guided by
evaluation of the DOFV, evaluation of the magnitude of
inter-individual and residual variance, and examination
of diagnostic residual plots. The chi-squared test
(P \ 0.005) for the log-likelihood DOFV between nested
models with degrees of freedom equal to the difference
in number of parameters between models was used to
declare superiority of one model over another. This
corresponds to a reduction in OFV of C7.88 (P \ 0.005)
for comparison of models that differ by one parameter.
The superior model should also have an associated
reduction in the magnitude of inter-individual and
residual variance estimates, as well as improved diag-
nostic plots. The DOFV was not used to evaluate
parameters describing variability. The covariance step
was implemented for each model, and standard errors
(SEs) for parameter estimates, as well as correlation
between parameters, were evaluated. Models with
parameter estimates with high associated SEs ([35 % of
the parameter estimate), models with a high degree of
correlation between parameters ([90 %), and models
that included a covariate(s) whose effect on the esti-
mated parameter value was negligible were carefully
evaluated and re-parameterized, or possibly rejected.
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2.4.4 Model Qualification
The model developed in this analysis was tested and
qualified by evaluating precision of the final parameter
estimates and the condition number, and determining both
the symmetrical 95 % confidence intervals (CIs) from the
asymptotic SEs of the parameter estimates, as well as non-
parametrically bootstrapped 95 % CI. Standard diagnostic
plots and visual and numerical predictive checks were also
evaluated. Finally, the power to evaluate CL/F and Vc/
F was evaluated using the final model and database to
confirm the prospective evaluation.
In addition, a visual predictive check (VPC) [11] was
conducted to compare the distribution of simulated obser-
vations from the final model to those obtained from the
original data.
2.5 Systems
The concentration–time data collected in these studies
were analyzed using mixed–effects modeling methods as
implemented by the computer program NONMEM (ver-
sion 7, level 2; Icon Development Solutions, Ellicott City,
MD, USA) [12, 13], compiled using Intel Fortran Parallel
Studio 2011 (Intel Corporation, Santa Clara, CA, USA),
and installed on a grid server system running Windows
Server 2008 x64-bit. Diagnostic graphics, exploratory
analyses, and post-processing of NONMEM output was
performed using the SPlus 6.2 Professional software [14] or
R version 2.15.0 or later.
3 Results
3.1 Demographics
A total of 156 patients (80 females, 76 males) took part in
this study. Age groups were \1 year (n = 10), 1 year to
\2 years (n = 14), 2 years to \4 years (n = 28), 4 years
to \7 years (n = 28), 7 years to \12 years (n = 10), and
C12 years (n = 66). The overall summary statistics for
baseline demographics are presented in Table 2.
Table 2 Demographic characteristics of study patients
Characteristic Study PKU-015 (N = 80)a Study PKU-004 (N = 78)a Pooled studies PKU-015 and
PKU-004 (N = 156)a
Age (years) 3.28 (2.01) [0.107–6.98] 21.1 (9.64) [9–50] 12 (11.3) [0.107–50]
Age category [n (%)]
\1 year 10 (12.5) 0 10 (6.4)
1 to \2 years 14 (17.5) 0 14 (9.0)
2 to \4 years 28 (35.0) 0 28 (17.9)
4 to \7 years 28 (35.0) 0 28 (17.9)
7 to \12 years 0 10 10 (6.4)
C12 years 0 68 66 (42.3)
Sex [n (%)]
Females 49 (61.3) 33 (42.3) 80 (51.3)
Males 31 (38.7) 45 (57.7) 76 (48.7)
Ethnicity [n (%)]
Non-Hispanic 78 (97.5) 76 152 (97.4)
Hispanic 2 (2.5) 2 4 (2.6)
Body weight (kg) 15.9 (6.36) [4.5–41.9] 67.2 (21.8) [28.2–144] 40.9 (30.3) [4.5–144]
Height (cm) 95.6 (18.3) [56–128] 165 (13.3) [126–191] 129 (38.2) [56–191]
Body surface area (m2) 0.635 (0.19) [0.259–1.18] 1.72 (0.31) [1.05–2.65] 1.17 (0.604) [0.259–2.65]
ALT (IU/L) 22.4 (8.15) [13–63] 28.4 (18.3) [11–127] 25.4 (14.5) [11–127]
AST (IU/L) 38.1 (8.75) [23–63] 25.7 (5.8) [14–43] 32.2 (9.65) [14–63]
Bilirubin (mg/dL) 7.51 (4.4) [1.71–34.2] 0.55 (0.33) [0.1–1.9] 4.12 (4.7) [0.1–34.2]
Albumin (g/dL) 4.19 (0.274) [3.6–4.9] 4.49 (0.23) [4–5] 4.33 (0.29) [3.6–5]
CLCR (mL/min)
b 57.1 (22.2) [9.39–120] 114 (26) [48–231] 87.8 (45.1) [9.39–276]
Baseline phenylalanine (lmol/L) 324 (140) [57.5–768] 811 (393) [53–2190] 562 (378) [53–2190]
ALT alanine aminotransferase, AST aspartate aminotransferase, CLCR creatinine clearance
a Values are presented as mean (standard deviation) [range], unless specified otherwise
b Calculated from plasma creatinine
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3.2 Final Model
The final dataset consisted of 475 observations from 156
patients from studies PKU-015 and PKU-004. The final
pharmacokinetic model was a one-compartment model
with first-order input and elimination. The model was
parameterized in terms of CL/F, Vc/F, first-order absorp-
tion rate constant (ka), an absorption lag time (tlag), and
endogenous level of BH4 (C0). The effects of weight on
CL/F and Vc/F were described using a power function. No
other covariates were identified as being predictive of
pharmacokinetic variability. The residual error model was
a CCV model (additive in the log domain) with separate
terms for each study. Inter-individual variability was
described for CL/F, Vc/F, and C0 with terms describing the
correlation between CL/F and Vc/F. The equations for the
final model parameters are provided in Eq. 6 and the
parameter estimates for the final covariate model are pre-
sented in Table 3.
CL=F ¼ h1  WeightðkgÞ
70
 h6
 exp g1ð Þ
Vc=F ¼ h2  WeightðkgÞ
70
 h7
 exp g2ð Þ
ka ¼ h3
tlag ¼ h4
C0 ¼ h5  exp g3ð Þ
ð6Þ
Parameter precision for the final model was generally
good, with most parameters being estimated with relative
SEs\25 %, with the exception of Vc/F and the associated
inter-individual variability. For the addition of two
covariate factors (weight on CL/F and weight on Vc/F),
the objective function decreased 137.26 points. Inter-
individual variability on CL/F decreased from 87 to 46 %
and on Vc/F decreased from 78 to 57 %. The residual
variability in the final model was acceptable, being 21 %
for data arising from study PKU-004 and 30 % from data
arising from study PKU-015; this variability was not
affected by the addition of weight as a covariate to CL/
F and Vc/F. Evaluation of the population mean value of
half-life suggests a terminal half-life of 0.78 h, whereas the
absorption half-life (calculated as 0.693/ka) is 2.95 h,
suggesting flip-flop pharmacokinetic behavior [15], in
which absorption becomes the rate-limiting metric of
exposure. However, attempts to re-parameterize the
model to force absorption to be faster than elimination
were not successful. Given the absorption and elimination
half-lives, once-daily dosing in pediatric patients is
justified.
3.3 Final Model Stability and Predictability
The median values obtained from the non-parametric
age-stratified bootstrap evaluation are in good agree-
ment with the original estimated values (Table 3). The
CIs for the parameters do not include the null, sup-
porting the inclusion of weight as a covariate for CL/
F and Vc/F. In general, the CIs are reassuringly narrow,
although the intervals for Vc/F are wide, as would be
inferred from the SEs of the parameter estimates. The
condition number was low, suggesting minimal co-lin-
earity; the shrinkage was low for CL/F, but high for Vc/
F in the final model.
Table 3 Estimated population pharmacokinetic parameters and bootstrap 95 % confidence interval for sapropterin dihydrochloride
Parameter (units) Parameter Final model estimate (SE) Bootstrap model estimate (95 % CI)
CL/F (L/h) h1 2,710 (9.8) 2,708 (2,308–3,162)
Effect of weight on CL/F h6 0.864 (7.3) 0.861 (0.751–0.980)
Vc/F (L) h2 3,010 (43.9) 3,967 (1,509–8,596)
Effect of weight on Vc/F h7 0.644 (18.9) 0.658 (0.399–0.827)
ka h
-1 h3 0.235 (23.8) 0.284 (0.158–0.524)
tlag (h) h4 0.321 (11.2) 0.313 (0.246–0.400)
C0 (lg/L) h5 16.6 (4.1) 16.39 (15.5–18.22)
Residual error study PKU-004 (% CV) h8 21.1 (9.2) 20.47 (17.95–26.0)
Residual error study PKU-015 (% CV) h9 30.2 (12) 30.312 (23.5–37.86)
IIVCL/F (% CV) g1 45.61 (23.3) 45.85 (35.05–56.07)
IIVVc/F (% CV) g2 56.57 (39.4) 54.67 (32.14–78.56)
IIVC0 (% CV) g3 36.47 (30) 36.16 (26.54–48.17)
Corr (CL/F, Vc/F) 0.469 (NE) 0.34 (0.20–0.50)
C0 endogenous levels, CI confidence interval, CL/F apparent total clearance of the drug from plasma after oral administration, Corr correlation
between parameters, CV coefficient of variation, IIV inter-individual variability, ka absorption rate constant, NE not estimated, SE standard error,
tlag lag time, Vc/F apparent volume of distribution of the central compartment
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3.4 Predictive Performance of the Final Model
Goodness-of-fit plots are provided in Electronic Sup-
plementary Material Fig. 2S and 3S. A plot of observed
versus typical predicted BH4 concentration and the plot
of observed versus individual predicted BH4 concen-
tration show generally good agreement, with no appar-
ent bias. Despite including weight in the model to
describe CL/F and Vc/F, there was still significant
unexplained variability in pharmacokinetic model
parameters. The plots of conditional weighted residuals
versus typical predicted concentrations and conditional
weighted residuals versus time after dose show no evi-
dent trends or bias, and the range of conditional
weighted residuals falls between ±3.
Frequency histogram plots of normalized prediction
distribution errors, quantile–quantile plots, and plots
of observed concentrations overlaid with typical pre-
dicted concentrations versus time after dose suggested
that the final model described the observed data
properly.
3.5 Visual Predictive Check
To visualize the predictive performance of the final model,
several VPC plots were generated. In a plot showing the
2.5th, 50th, and 97.5th prediction intervals for BH4 con-
centrations overlaid with the observed data (Fig. 1), most
of the observed concentrations fall within the prediction
intervals, and there are no obvious patterns for observations
that fall outside the prediction intervals, which indicates
that the model can capture the variability in the observed
data. The percentiles of the observed data are consistent
with the prediction intervals of the simulated data. The
VPC plots stratified by age or weight suggest that the
observed and simulated percentiles are in reasonable
agreement, even for the lowest age and weight groups in
which the amount of data is sparse. A VPC plot stratified
by study suggested that, despite simplification of the model
originally used to describe data arising from PKU-004, the
data are adequately reproduced by the new model, and
confirmed that there are no inherent differences between
the two study populations.
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Fig. 1 Visual predictive check by age group. Open blue circles are
observed data, the solid red line is the median observed concentration,
dashed red lines are the upper and lower 95 % observed intervals, the
solid black line is the median of the simulated data, and dashed black
lines are the upper and lower 95th percentiles of the simulated data.
BH4 tetrahydrobiopterin
PopPK of Sapropterin in Children with Phenylketonuria 201
3.6 Confirmation of Study Power
The desired precision was to target the 95 % CI of the CL/
F and Vc/F to be within the intervals of 60 and 166 % of
the point estimate for the geometric mean for each desig-
nated age group. A prospective evaluation of study power
indicated that PKU-015 had sufficient power to meet these
criteria. The power was re-evaluated and the results dem-
onstrate that the study had sufficient power to meet the pre-
specified criteria for each age group (Fig. 2).
3.7 Clinical Significance of Identified Covariates
To assess the clinical significance of the effect of weight,
the final population model was used to calculate pharma-
cokinetic parameter values for patients that represented the
extremes of covariate influences within this study popula-
tion. The effect of weight on CL/F and Vc/F is presented in
Electronic Supplementary Material Table 2S. At the
extremes of weight, a 5 kg patient had a CL/F and Vc/
F value approximately 10 and 18 % of the reference 70 kg
patient, respectively. Conversely, a patient weighing
145 kg had CL/F and Vc/F that was 190 and 160 % of the
reference patient, respectively. Although the addition of
weight to the model significantly decreased the inter-indi-
vidual variability in CL/F and Vc/F, significant between-
patient variability remained.
Both CL/F (Fig. 3a) and Vc/F (Fig. 3b) increase in a
non-linear manner with increasing weight, although indi-
vidual predictions still vary around the typical individual
predictions. The intervals for Vc/F are broad, reflecting the
precision with which Vc/F was estimated. Although the
majority of individual estimated values for Vc/F fall at or
below the median, there are patients (particularly patients
with low body weight) whose estimated Vc/F values fill the
predicted 95 % CI for this parameter.
3.8 Exposure
In simulated concentration–time profiles following 20 mg/
kg dosing for a range of weights, concentrations remain
above the endogenous level for the dose interval (Elec-
tronic Supplementary Material Fig. 4S). Overall, BH4
exposure (area under the concentration–time curve at
steady state; AUCss) based on administered dose and
individual clearance estimates was comparable across all
age groups, although there is a slight visual trend towards
higher exposure (AUCss) as the age decreases (Fig. 4).
However, the number of patients in the youngest age group
is small, so this trend should be considered with caution.
Maximum (peak) drug concentration (Cmax) could not be
determined as the shrinkage on Vc/F was high and there
were no terms for inter-individual variability on ka, making
parameters used to calculate Cmax unlikely to reflect indi-
vidual values. No other covariates were identified.
3.9 Comparison of Previous and Current
Pharmacokinetic Models
In order to evaluate the differences in exposure expected
from the original two-compartment model and the current
one-compartment model, simulated concentration–time
profiles for the reference patient were generated. Differences
between the expected concentration times arising from these
two models is minimal (Fig. 5). The simplification from a
two-compartment structural model to a one-compartment
structural model used in the current evaluation is justified
based further on the poor precision with which the inter-
compartmental clearance term (Q/F) and the apparent vol-
ume of distribution of the peripheral compartment (Vp/F)
were identified in the original model. The inability to utilize
the previous model may be partly attributed to the change in
NONMEM versions (6.1–7.2) that involved underlying
changes to the FOCE estimation method and changes in the
compilers used for NONMEM.
4 Discussion
This analysis suggests that the pharmacokinetics of BH4
can be described by a one-compartment model first-order
input following a tlag and first-order elimination. A term
describing the endogenous concentration is also included in
the model. Inter-individual variability was included on CL/
F, Vc/F, and C0, with correlation described between CL/
F and Vc/F. The model was fit using the FOCE method and
the LTBS approach was used. A proportional residual error
model (additive in the log domain) was incorporated with
separate residual error terms estimated for each study.
A D-optimal, sparsely sampled population pharmacoki-
netic approach was used in this study for several reasons: this
approach suggests windows of time where sampling will be
most informative relative to a proposed model, without
undue penalty against the identification of alternative mod-
els; allows patients to have fewer blood samples drawn than
with traditional pharmacokinetic sample designs, which
often require eight or more pharmacokinetic samples per
patient; and weighs various sample schemes based on the
efficiency of a proposed design, the expected bias and pre-
cision of estimated parameters, and practical considerations.
The fact that patients in this study received different dosing
regimens of sapropterin further improved the information
content of the data obtained. The final model was evaluated
using multiple methods including non-parametric boot-
strapping and VPCs. All evaluations suggested the model
adequately described the data and was acceptable.
















































Fig. 2 Frequency histograms of individual parameter estimates.
Confirmation of power for apparent total clearance of the drug from
plasma after oral administration and apparent volume of distribution
of the central compartment in the age group 0–1 years (a), 1–2 years
(b), 2–4 years (c), and 4–7 years (d). The solid purple line is the
median value, dotted black lines are the 95 % confidence interval, and
the red dashed lines are 60–166 % of point estimate of the mean
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Limitations of this study include variability in Phe levels
and a small sample size. Phe levels are impacted by mul-
tiple factors and can change rapidly in patients with PKU.
The timing of Phe determinations relative to pharmacoki-
netic sampling was not known. Although study PKU-015
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with other pediatric studies, a relatively small number of
pediatric subjects (n = 80) are included in this analysis.
Total body weight was the only significant covariate and
improved the model fit to the data when included on both
CL/F and Vc/F. The effect of body weight on CL/F and Vc/
F was substantial and supports a dose adjustment strategy
based on weight in the pediatric population. While the
addition of weight to the model significantly decreased the
inter-individual variability in CL/F and Vc/F, there was
still significant between-patient variability remaining.
Evaluation of the population mean value of half-life sug-





























Fig. 3 Relationship between
weight and clearance (a) and
weight and volume of
distribution (b). Dotted lines are
the upper and lower 95 %
confidence intervals of median
expected parameter value, the
solid line is the median expected
parameter value, and open
circles are the individual
estimated parameter values
from final model. CI confidence
interval, CL/F clearance,
















Fig. 4 Comparison of
tetrahydrobiopterin exposure by
age groups. Whiskers represent
10th and 90th percentile, boxes
represent 25th and 75th
percentile, center lines represent
median, and solid dots represent
outliers. AUC area under the
concentration–time curve
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half-life (calculated as 0.693/ka) is 2.95 h, suggesting flip-
flop pharmacokinetic behavior where absorption becomes
the rate-limiting metric of exposure. The estimated elimi-
nation half-life from the current model is different from the
previous model, which could be due to the use of endog-
enous concentrations to estimate half-life in the previous
model.
Based on recommended dosing, exposure across age
groups was comparable. Given the absorption half-life and
elimination half-life, once-daily dosing is justified in
pediatric patients.
5 Conclusion
Overall, the pharmacokinetic model developed in the
present evaluation provides reasonable estimates that are
consistent with the previous evaluation [4], despite the
Concentration from current model




















Concentration from current model



















Fig. 5 Linear (a) and semi-log
(b) comparison of simulated
concentration–time profiles for
a 20 mg/kg dose for the
reference patient. BH4
tetrahydrobiopterin
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simplification of the model. The effect of body weight on
CL/F and Vc/F was substantial and supports a dose
adjustment strategy based on weight in the pediatric pop-
ulation. The doses selected for pediatric patients provided
similar exposure. Overall, the exposure across all age
groups was comparable and given the absorption and
elimination half-lives, once-daily dosing is justified for
pediatric patients.
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